These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 3928105)

  • 1. [Abnormal regulation in the production of IL2 in Hodgkin's disease].
    Marchiol C; Kaplan C; Chouaib S; Janvier M; Ferme C; Muller JY; Fradelizi D
    C R Acad Sci III; 1985; 301(6):283-8. PubMed ID: 3928105
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prostaglandin-producing suppressor cells in Hodgkin's disease.
    Goodwin JS; Messner RP; Bankhurst AD; Peake GT; Saiki JH; Williams RC
    N Engl J Med; 1977 Nov; 297(18):963-8. PubMed ID: 409950
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Antibody response in cultures of lymphocytes from patients with Hodgkin's lymphoma: role of monocytes].
    Villa ML; Colleoni M; Valenti F; Tondini C; Clerici E
    Boll Ist Sieroter Milan; 1987; 66(3):214-21. PubMed ID: 3325076
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of levamisole, thymic humoral factor and indomethacin on e-rosette formation of lymphocytes in Hodgkin's disease.
    Ramot B; Rosenthal E; Biniaminov M; Ben-Bassat I
    Isr J Med Sci; 1981 Apr; 17(4):232-5. PubMed ID: 7195385
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Depressed T cell proliferative responses in Hodgkin's disease: role of monocyte-mediated suppression via prostaglandins and hydrogen peroxide.
    Fisher RI; Bostick-Bruton F
    J Immunol; 1982 Oct; 129(4):1770-4. PubMed ID: 6980949
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Cellular regulation of human interleukin-2 production].
    Chouaib S; Fradelizi D
    C R Seances Acad Sci III; 1982 Oct; 295(5):365-8. PubMed ID: 6817873
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Defect in lectin-induced interleukin 2 (IL-2) production by peripheral blood lymphocytes of patients with Hodgkin's disease.
    Soulillou JP; Douillard JY; Vie H; Harousseau JL; Guenel J; le Mevel-le Pourhiet A; le Mevel B
    Eur J Cancer Clin Oncol; 1985 Aug; 21(8):935-9. PubMed ID: 3876220
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Suppressor cells of the mixed lymphocyte reaction in patients with Hodgkin's disease.
    Engleman EG; Benike C; Hoppe RT; Kaplan HS
    Transplant Proc; 1979 Dec; 11(4):1827-9. PubMed ID: 161096
    [No Abstract]   [Full Text] [Related]  

  • 9. Impairment in proliferation, lymphokine production and frequency distribution of mitogen-responsive and interleukin-2-producing cells in Hodgkin's disease.
    Damle RN; Advani SH; Gangal SG
    Cancer Immunol Immunother; 1991; 34(3):205-10. PubMed ID: 1756538
    [TBL] [Abstract][Full Text] [Related]  

  • 10. T cell responses in Hodgkin's disease: frequency distribution of IL-2 producing cells and quantitation of IL-2 produced per cell.
    Rajaram N; Damle RN; Advani SH; Gangal SG
    Indian J Biochem Biophys; 1994 Aug; 31(4):221-5. PubMed ID: 8002002
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impaired proliferative response and low interleukin-2 production in patients with lymphoma.
    Musatti CC; Yasaka K; Santos LM
    Braz J Med Biol Res; 1987; 20(3-4):351-62. PubMed ID: 3502537
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monocyte function in Hodgkin's disease.
    Holm G; Björkholm M; Johansson B; Mellstedt H; Lindemalm C
    Clin Exp Immunol; 1982 Jan; 47(1):162-8. PubMed ID: 7094420
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of peripheral blood lymphocyte stimulation on zeta chain expression and IL-2 production in Hodgkin's disease.
    Frydecka I; Boćko D; Kosmaczewska A; Ciszak L; Morilla R
    Br J Cancer; 2001 May; 84(10):1339-43. PubMed ID: 11355944
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impaired interleukin regulation of the phytohemagglutinin response in Hodgkin's disease.
    Zamkoff KW; Reeves WG; Paolozzi FP; Poiesz BJ; Comis RL; Tomar RH
    Clin Immunol Immunopathol; 1985 Apr; 35(1):111-24. PubMed ID: 3922653
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Implications of persistent T cell abnormalities for the etiology of Hodgkin's disease.
    Fisher RI
    Cancer Treat Rep; 1982 Apr; 66(4):681-7. PubMed ID: 6210434
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The mechanisms of inhibition of human IL 2 production. II. PGE2 induction of suppressor T lymphocytes.
    Chouaib S; Chatenoud L; Klatzmann D; Fradelizi D
    J Immunol; 1984 Apr; 132(4):1851-7. PubMed ID: 6230395
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evidence for the involvement of monocyte-derived toxic oxygen metabolites in the lymphocyte dysfunction of Hodgkin's disease.
    Deshazo RD; Ewel C; Londono S; Metzger Z; Hoffeld JT; Oppenheim JJ
    Clin Exp Immunol; 1981 Nov; 46(2):313-20. PubMed ID: 7337972
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Subpopulations of human T lymphocytes in patients with Hodgkin's disease before and after treatment.
    Karande AA; Gulwani B; Advani SH; Gangal SG
    Neoplasma; 1982; 29(2):149-59. PubMed ID: 6981068
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Some immunological parameters in Hodgkin's disease.
    Dienstbier Z; Hermanská Z; Pĕnicka P; Zámecník J
    Neoplasma; 1988; 35(1):51-60. PubMed ID: 3352837
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum interleukin 6 levels are elevated in lymphoma patients and correlate with survival in advanced Hodgkin's disease and with B symptoms.
    Kurzrock R; Redman J; Cabanillas F; Jones D; Rothberg J; Talpaz M
    Cancer Res; 1993 May; 53(9):2118-22. PubMed ID: 8481913
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.